207 related articles for article (PubMed ID: 32690647)
1. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Bigelow KM; Tasneen R; Chang YS; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690647
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
[TBL] [Abstract][Full Text] [Related]
3. Model-based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug-resistant tuberculosis.
Mehta K; Guo T; van der Graaf PH; van Hasselt JGC
Br J Clin Pharmacol; 2024 Feb; 90(2):463-474. PubMed ID: 37817504
[TBL] [Abstract][Full Text] [Related]
4. Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA; Schechter MC; Ashkin D; Peloquin CA; Peter Cegielski J; Andrino BB; Burgos M; Caloia LA; Chen L; Colon-Semidey A; DeSilva MB; Dhanireddy S; Dorman SE; Dworkin FF; Hammond-Epstein H; Easton AV; Gaensbauer JT; Ghassemieh B; Gomez ME; Horne D; Jasuja S; Jones BA; Kaplan LJ; Khan AE; Kracen E; Labuda S; Landers KM; Lardizabal AA; Lasley MT; Letzer DM; Lopes VK; Lubelchek RJ; Patricia Macias C; Mihalyov A; Misch EA; Murray JA; Narita M; Nilsen DM; Ninneman MJ; Ogawa L; Oladele A; Overman M; Ray SM; Ritger KA; Rowlinson MC; Sabuwala N; Schiller TM; Schwartz LE; Spitters C; Thomson DB; Tresgallo RR; Valois P; Goswami ND;
Clin Infect Dis; 2023 Oct; 77(7):1053-1062. PubMed ID: 37249079
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
[TBL] [Abstract][Full Text] [Related]
8. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
Ali MZ; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp J; Patterson J; Henao-Tamayo M; Lee RE; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
bioRxiv; 2024 Jun; ():. PubMed ID: 38014249
[TBL] [Abstract][Full Text] [Related]
9. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
13. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
[TBL] [Abstract][Full Text] [Related]
15. Dynamic
Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
[TBL] [Abstract][Full Text] [Related]
17. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
[TBL] [Abstract][Full Text] [Related]
18. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
[TBL] [Abstract][Full Text] [Related]
19. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.
Labuda SM; Seaworth B; Dasgupta S; Goswami ND;
Lancet Respir Med; 2024 Feb; 12(2):e5-e6. PubMed ID: 38043563
[No Abstract] [Full Text] [Related]
20. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
Haley CA; Macias P; Jasuja S; Jones BA; Rowlinson MC; Jaimon R; Onderko P; Darnall E; Gomez ME; Peloquin C; Ashkin D; Goswami ND
Emerg Infect Dis; 2021 Jan; 27(1):332-4. PubMed ID: 33227229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
